Protagenic Therapeutics, Inc. (PTIX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en New York City, NY, United States. El CEO actual es Garo H. Armen.
PTIX tiene fecha de IPO 2021-04-27, 1 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $1.08M.
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
